Flow Research
Phenylpiracetam: 200mg
- Zvejniece, Liga et al. “S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity.” Pharmacology, biochemistry, and behavior vol. 160 (2017): 21-29. doi:10.1016/j.pbb.2017.07.009
- Malykh, Andrei G, and M Reza Sadaie. “Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.” Drugs vol. 70,3 (2010): 287-312. doi:10.2165/11319230-000000000-00000
- Vernon, M W, and E M Sorkin. “Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.” Drugs & aging vol. 1,1 (1991): 17-35. doi:10.2165/00002512-199101010-00004
- Gouliaev, A H, and A Senning. “Piracetam and other structurally related nootropics.” Brain research. Brain research reviews vol. 19,2 (1994): 180-222. doi:10.1016/0165-0173(94)90011-6
- Vernon, Margaret W., and Eugene M. Sorkin. "Piracetam." Drugs & aging 1.1 (1991): 17-35.
Alpha GPC: 300mg
- PM, Kidd (2009) “Integrated brain restoration after ischemic stroke-medical management, risk factors, nutrients, and other interventions for managing inflammation and Enhancing Brain Plasticity” Alternative Medicine Review, 2009 - Thorne Research Inc.
- Marcus, Lena et al. “Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance.” Journal of the International Society of Sports Nutrition vol. 14 39. 5 Oct. 2017, doi:10.1186/s12970-017-0196-5
- Bellar, David et al. “The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength.” Journal of the International Society of Sports Nutrition vol. 12 42. 17 Nov. 2015, doi:10.1186/s12970-015-0103-x
- Ziegenfuss, Tim, Jamie Landis, and Jennifer Hofheins. "Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise." Journal of the International Society of Sports Nutrition 5.S1 (2008): P15.
- Strifler, Gerda et al. “Targeting Mitochondrial Dysfunction with L-Alpha Glycerylphosphorylcholine.” PloS one vol. 11,11 e0166682. 18 Nov. 2016, doi:10.1371/journal.pone.0166682
Huperzine A: 5mcg
- Wang, Rui, and Xi Can Tang. "Neuroprotective effects of huperzine A." Neurosignals 14.1-2 (2005): 71-82.
- Yang, Guoyan et al. “Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.” PloS one vol. 8,9 e74916. 23 Sep. 2013, doi:10.1371/journal.pone.0074916
- Gul, Amara et al. “Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.” Journal of the Chinese Medical Association : JCMA, S1726-4901(18)30226-0. 7 Sep. 2018, doi:10.1016/j.jcma.2018.07.004
- Damar, U et al. “Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research.” Expert review of neurotherapeutics vol. 16,6 (2016): 671-80. doi:10.1080/14737175.2016.1175303
- Damar, Ugur et al. “Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease.” Medical hypotheses vol. 99 (2017): 57-62. doi:10.1016/j.mehy.2016.12.006
Acetyl L-carnitine: 300mg
- Ferreira, Gustavo C, and Mary C McKenna. “L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.” Neurochemical research vol. 42,6 (2017): 1661-1675. doi:10.1007/s11064-017-2288-7
- Nasca, Carla et al. “Acetyl-l-carnitine deficiency in patients with major depressive disorder.” Proceedings of the National Academy of Sciences of the United States of America vol. 115,34 (2018): 8627-8632. doi:10.1073/pnas.1801609115
- Sergi, G et al. “Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders.” Aging clinical and experimental research vol. 30,2 (2018): 133-138. doi:10.1007/s40520-017-0770-3
- Mohammadi, Rahim, and Keyvan Amini. “Topically-administered acetyl-L-carnitine increases sciatic nerve regeneration and improves functional recovery after tubulization of transected short nerve gaps.” Journal of neurosurgical sciences vol. 61,4 (2017): 395-402. doi:10.23736/S0390-5616.16.02845-9
- Pettegrew, Jay W., et al. "Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease." Neurobiology of aging 16.1 (1995): 1-4.
Rhodiola Rosea: 200mg
- Amsterdam, Jay D, and Alexander G Panossian. “Rhodiola rosea L. as a putative botanical antidepressant.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 23,7 (2016): 770-83. doi:10.1016/j.phymed.2016.02.009
- Nabavi, Seyed Fazel et al. “Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy.” Phytotherapy research : PTR vol. 30,4 (2016): 532-9. doi:10.1002/ptr.5569
- Panossian, A et al. “Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 17,7 (2010): 481-93. doi:10.1016/j.phymed.2010.02.002
- Ishaque, Sana et al. “Rhodiola rosea for physical and mental fatigue: a systematic review.” BMC complementary and alternative medicine vol. 12 70. 29 May. 2012, doi:10.1186/1472-6882-12-70
- Li, Yonghong et al. “Rhodiola rosea L.: an herb with anti-stress, anti-aging, and immunostimulating properties for cancer chemoprevention.” Current pharmacology reports vol. 3,6 (2017): 384-395. doi:10.1007/s40495-017-0106-1
Bacopa Monnieri: 100mg
- Nemetchek, Michelle D et al. “The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain.” Journal of ethnopharmacology vol. 197 (2017): 92-100. doi:10.1016/j.jep.2016.07.073
- Kongkeaw, Chuenjid et al. “Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract.” Journal of ethnopharmacology vol. 151,1 (2014): 528-35. doi:10.1016/j.jep.2013.11.008
- Chaudhari, Kaustubh S et al. “Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease.” Annals of neurosciences vol. 24,2 (2017): 111-122. doi:10.1159/000475900
- Kwon, Hyun Jung et al. “Bacopa monnieri extract improves novel object recognition, cell proliferation, neuroblast differentiation, brain-derived neurotrophic factor, and phosphorylation of cAMP response element-binding protein in the dentate gyrus.” Laboratory animal research vol. 34,4 (2018): 239-247. doi:10.5625/lar.2018.34.4.239
- Abdul Manap, Aimi Syamima et al. “Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies.” Drug target insights vol. 13 1177392819866412. 31 Jul. 2019, doi:10.1177/1177392819866412
Noopept: 10mg
- Ostrovskaya, Rita U., et al. "The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model." Journal of psychopharmacology 21.6 (2007): 611-619.
- Ostrovskaya, Rita U et al. “Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.” Journal of biomedical science vol. 21,1 74. 6 Aug. 2014, doi:10.1186/s12929-014-0074-2
- Antipova, T. A., et al. "Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model." Bulletin of experimental biology and medicine 161.1 (2016): 58-60.
- Boiko, S S et al. “Pharmacokinetics of new nootropic acylprolly-dipeptide and its penetration across the blood-brain barrier after oral administration.” Bulletin of experimental biology and medicine vol. 129,4 (2000): 359-61. doi:10.1007/bf02439270
- Gharibyan, Anna. Amyloids here, amyloids there… What’s wrong with them?. Diss. Umeå University, 2012.
CoQ10: 20mg
- Sarmiento, Alvaro et al. “Coenzyme Q10 Supplementation and Exercise in Healthy Humans: A Systematic Review.” Current drug metabolism vol. 17,4 (2016): 345-58. doi:10.2174/1389200216666151103115654
- Hargreaves, Iain P, and David Mantle. “Coenzyme Q10 Supplementation in Fibrosis and Aging.” Advances in experimental medicine and biology vol. 1178 (2019): 103-112. doi:10.1007/978-3-030-25650-0_6
- Sharma, Abhinav et al. “Coenzyme Q10 and Heart Failure: A State-of-the-Art Review.” Circulation. Heart failure vol. 9,4 (2016): e002639. doi:10.1161/CIRCHEARTFAILURE.115.002639
- Mantle, David, and Iain Hargreaves. “Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview.” Antioxidants (Basel, Switzerland) vol. 8,2 44. 16 Feb. 2019, doi:10.3390/antiox8020044
- Flowers, Nadine et al. “Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.” The Cochrane database of systematic reviews ,12 (2014): CD010405. doi:10.1002/14651858.CD010405.pub2
B12: 5mg (NO REFERENCE)
bioperine 10mg
- Peterson, Christine T et al. “Effects of Turmeric and Curcumin Dietary Supplementation on Human Gut Microbiota: A Double-Blind, Randomized, Placebo-Controlled Pilot Study.” Journal of evidence-based integrative medicine vol. 23 (2018): 2515690X18790725. doi:10.1177/2515690X18790725
- Vasto, Sonya et al. “Dietary Supplements as Surrogate of Mediterranean Diet in Healthy Smoking Subjects.” Rejuvenation research vol. 21,1 (2018): 37-43. doi:10.1089/rej.2017.1950
- https://www.bioperine.com/index.php/mechanismsofactions